All In Biotech

Drug Trial Radar · NCT07058012

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab and Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

79

Planned (sponsor's estimate)

Start

Apr 17, 2026

Primary completion

Apr 17, 2029

Study completion Jun 1, 2029

Sponsor

Lead sponsor
NSABP Foundation IncResearch network
Sponsor type
Research network
Collaborators
Regeneron Pharmaceuticals
First posted
Jul 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after their treatment. Immunotherapeutic drugs (immunotherapies) act on different proteins on the surface of cells of the immune system and trigger the immune system to destroy cancer cells. The drugs being studied in NSABP FC-13 are cemiplimab, fianlimab, and REGN7075.

Conditions

  • Colo-rectal Cancer

Interventions

  • CemiplimabDrug

    Cemiplimab 350mg intravenously

  • cemiplimab plus fianlimabDrug

    Cemiplimab 350mg + Fianlimab 1600mg intravenously

  • cemiplimab + REGN7075Drug

    Cemiplimab 350mg + REGN7075 2700mg intravenously

  • ctDNA testingOther

    Eligible patients using results for ctDNA-positivity as obtained from a commercial assay run in any CLIA-certified lab will proceed to enrollment and begin treatment. All patients will have confirmation of ctDNA-positivity via the Signatera\^TM assay (Clinical Trial Assay), but treatment may proceed while awaiting confirmatory results.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clearance of cDNATime frame: From enrollment to 12 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida · Recruiting

  • University of Iowa - Holden Comprehensive Cancer Center

    Iowa City, Iowa · Recruiting

  • University of Kansas Cancer Center

    Kansas City, Kansas · Recruiting

  • University of Maryland Greenbaum

    Baltimore, Maryland · Recruiting

  • Missouri Baptist

    St Louis, Missouri · Recruiting

  • First Health of the Carolinas

    Pinehurst, North Carolina · Recruiting

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • Magee-Womens Hospital of UPMC

    Pittsburgh, Pennsylvania · Recruiting

  • Ballad Health Cancer Center - Kingsport

    Kingsport, Tennessee · Recruiting

  • Huntsman Cancer Institute - University of Utah

    Salt Lake City, Utah · Recruiting

  • University of Virginia Health

    Charlottesville, Virginia · Recruiting

  • Bon Secours St. Francis Medical Center

    Midlothian, Virginia · Recruiting

  • Virginia Commonwealth University - Massey

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.